Navigation Links
OptiNose presents data on highly effective migraine treatment
Date:6/28/2008

BOSTON, MA Saturday June 28, 2008 OptiNose announced today that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.

Headache relief was achieved in 74.3% and 83.8% of patients at 60 minutes and 120 minutes after administration, respectively, and 48.6% of patients remained pain free after 48 hours. The results were statistically significant when compared to the study's placebo group. The study also confirmed earlier Phase I results. In the Phase I study, the OptiNose powder nasal drug delivery device achieved the maximum sumatriptan concentration in the blood at a median time of 20 minutes after administration. This result was comparable to injections and much faster than other intranasal delivery technologies.

"We are excited to develop this new treatment for the approximately 30 million Americans who suffer from migraines," said Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "Our new device combination will offer patients a much-needed alternative to existing, slower-acting nasal inhalers and tablets and painful injections."

The user feedback from patients who participated in the study was also very encouraging. "The majority of the migraine patients found the device to be both comfortable and easy to use." said Dr Djupesland. "We believe that we can offer a unique therapy for migraine sufferers, combining fast relief, low side effects and high user compliance."

Unlike traditional nasal delivery devices, the unique design of the OptiNose device ensures that drug is delivered to target sites throughout the entire nasal cavity, achieving optimal dose delivery while avoiding the risk of drug deposition to the lungs.


'/>"/>

Contact: Per Djupesland, M.D., Ph.D.
+474-809-0610
OptiNose
Source:Eurekalert

Related medicine news :

1. International Association for Dental Research presents awards and fellowships
2. MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alexs Lemonade Stand Foundation
3. Journal STEM CELLS Presents 3rd Annual Young Investigator Award at International Stem Cell Symposium
4. The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
5. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
6. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
7. The febit science lounge presents: Webinar About Role of Non-Protein-Coding RNA in Human Genome Set for 11 a.m. EDT on June 12
8. American College of Rheumatology presents recommendations for rheumatoid arthritis therapy
9. Childrens Health and Fitness To Be Focus of ING Presents Marc Anthony Juntos en Concierto Series
10. Montana Center for Work Physiology and Exercise Metabolism presents firefighter health study
11. Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: